Intravitreal injection of ziv-aflibercept in patient with refractory age-related macular degeneration
Copyright 2015, SLACK Incorporated.
| Veröffentlicht in: | Ophthalmic surgery, lasers & imaging retina. - 2013. - 46(2015), 1 vom: 15. Jan., Seite 91-4 |
|---|---|
| 1. Verfasser: | |
| Weitere Verfasser: | , , , , , |
| Format: | Online-Aufsatz |
| Sprache: | English |
| Veröffentlicht: |
2015
|
| Zugriff auf das übergeordnete Werk: | Ophthalmic surgery, lasers & imaging retina |
| Schlagworte: | Case Reports Journal Article Angiogenesis Inhibitors Recombinant Fusion Proteins VEGFA protein, human Vascular Endothelial Growth Factor A aflibercept 15C2VL427D Receptors, Vascular Endothelial Growth Factor EC 2.7.10.1 |
| Zusammenfassung: | Copyright 2015, SLACK Incorporated. The results of a patient with exudative age-related macular degeneration who received an intravitreal injection of ziv-aflibercept (Zaltrap; Sanofi-Aventis, Paris, France) in the right eye are described. A complete ocular examination as well as color fundus photography, optical coherence tomography, fluorescein angiography, microperimetry, full-field electroretinography, and multifocal electroretinography were performed and repeated 1 month later. The patient experienced subjective and objective improvement of visual acuity with a decrease in intraretinal and subretinal fluid. Microperimetric improvement also occurred. Electroretinographic changes were noted from baseline to the 30-day follow-up. No adverse events were observed at any time point. Ziv-aflibercept demonstrated short-term safety and efficacy after intravitreal administration for neovascular macular degeneration |
|---|---|
| Beschreibung: | Date Completed 18.06.2015 Date Revised 22.10.2015 published: Print Citation Status MEDLINE |
| ISSN: | 2325-8179 |
| DOI: | 10.3928/23258160-20150101-17 |